Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
This study is ongoing, but not recruiting participants.
Study NCT00005815 Information provided by National Cancer Institute (NCI)
First Received: June 2, 2000 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Intraocular Melanoma
Melanoma (Skin)
Additional conditions recognized in this trial
Eye Neoplasms
Melanoma
More general conditions related to this trial
Eye Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
temozolomide
thalidomide
More general drug interventions related to this trial
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
